New biologic: Ustekinumab (Stelara) was approved on September 25, 2009, for the treatment of adult patients aged 18 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Ustekinumab is a human interleukin (IL)-12 and IL-23 antagonist. Ustekinumab was approved on September 25, 2009, for the treatment of adult patients aged 18 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Ustekinumab is administered as a subcutaneous injection given at weeks 0 and 4, followed by every-12-week or quarterly dosing.
Efficacy. The clinical development program for ustekinumab included more than 2,200 patients, with two pivotal phase 3 trials serving as the primary basis for FDA approval. The trials showed that the majority of patients with moderate to severe plaque psoriasis who received ustekinumab sustained, clinically significant improvement in their disease severity. At week 12, the primary endpoint of both studies, at least two thirds of patients who received just two doses of ustekinumab, 45 mg or 90 mg, respectively, at weeks 0 and 4, achieved 75% improvement on the Psoriasis Activity and Severity Index (PASI), compared with 3% to 4% of patients receiving placebo (P<.001). An additional phase 3 study evaluated the safety and efficacy of ustekinumab compared with etanercept in 903 patients with plaque psoriasis (etanercept=347, ustekinumab 45 mg=209, ustekinumab 90 mg=347). Patients were randomly assigned to receive ustekinumab 45 mg or 90 mg doses at weeks 0 and 4, while the etanercept group received twice-weekly doses of 50 mg over 12 weeks. The primary endpoint of the study was the proportion of patients who achieved a PASI at week 12. Study results showed that 68% and 74% of patients receiving ustekinumab 45 mg or ustekinumab 90 mg, respectively, at weeks 0 and 4 achieved PASI 75 compared with 57% of patients receiving twice-weekly doses of etanercept 50 mg over 12 weeks (P=.012 for ustekinumab 45 mg; P<.001 for ustekinumab 90 mg each, each compared with etanercept).
Safety. Ustekinumab should not be given to patients with any clinically important active infection. Ustekinumab is an immunosuppressant and may heighten the risk for serious infections and malignancy. Patients should be evaluated for tuberculosis infection prior to initiating treatment with ustekinumab.
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More